A reduction in the CD4+/CD8+ ratio is common in lung cancer patients after chemotherapy cycles, indicating an inhibition of the immune function in which the immune system's ability to recognise and kill mutant cells is weakening, leading to tumour growth and metastasis. The gene discussed is CD4; the disease is lung cancer.